SCHEMBL24257513

SCHEMBL24257513

Cc1c(-c2ccncc2)cnc(C#N)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.38
PDE3B Q13370 4/20 0.38
PDE3A Q14432 4/20 0.38
LMNA P02545 2/20 0.38
PTGS1 P23219 2/20 0.38
PDE5A O76074 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
PDE4A P27815 1/20 0.38
CYP2C19 P33261 1/20 0.38
BLM P54132 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
DHODH Q02127 1/20 0.35
PDE10A Q9Y233 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30453043 1.00 KDM4E (0.38) KDM4EPDE3BPDE3ALMNAPTGS1
SCHEMBL24257695 0.84 KDM4E (0.45) KDM4EHPGDTSHRCYP2C19MAPK1
SCHEMBL30453176 0.84 KDM4E (0.45) KDM4EHPGDTSHRCYP2C19MAPK1
SCHEMBL24257735 0.81 ALOX15 (0.48) CYP2C19CYP11B1CYP11B2
SCHEMBL30546870 0.80 KDM4E (0.35) KDM4EPTGS1HPGDPDE4DALDH1A1
SCHEMBL24257763 0.80 KDM4E (0.35) KDM4EPTGS1HPGDPDE4DALDH1A1
SCHEMBL30454648 0.78 DHFR (0.44) KDM4ELMNAHPGDALDH1A1NPC1
SCHEMBL24257698 0.78 DHFR (0.44) KDM4ELMNAHPGDALDH1A1NPC1
SCHEMBL24257731 0.78 LRRK2 (0.42) KDM4ELMNAHPGDTSHRCYP2C19
SCHEMBL24257776 0.77 KDM4E (0.41) KDM4ELMNAHPGDTSHRBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 KDM4E 175/4885PDE3B 991/4885PDE3A 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.